Share Name Share Symbol Market Type Share ISIN Share Description
Provexis Plc LSE:PXS London Ordinary Share GB00B0923P27 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 0.525p 0.45p 0.60p - - - 0 06:42:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Food Producers 0.1 -0.5 -0.0 - 9.56

Provexis Share Discussion Threads

Showing 45951 to 45974 of 45975 messages
Chat Pages: 1839  1838  1837  1836  1835  1834  1833  1832  1831  1830  1829  1828  Older
DateSubjectAuthorDiscuss
26/7/2017
18:12
HTTP://www.nutraingredients-asia.com/Regulation-Policy/Watch-Sports-nutrition-ready-to-rocket-in-China-as-e-commerce-sales-continue-to-set-the-pace Which reflects this statement:- "The Company expects to report revenues for the year ended 31 March 2017 of £228k, a 148% year on year increase (2016: £92k)." · The Company and DSM have seen an encouraging increase in brand awareness and customer interest in "Fruitflow® in recent months, with the total projected annual sales value of the prospective sales pipeline for Fruitflow standing at an all-time high level;" Lets hope this "Alltime high Level" results in a year on year increase in the value of the company and increase in share price; However, I still believe once we start making a profit DSM will buy us out.IMHO 3rd July 2017 HTTP://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/PXS/13280648.html
wheelds
26/7/2017
12:34
Redprince No-one can be sure of anything, least of all when we're going to be profitable, and China is a very big market, but is it bigger then the market in the States ? I'm not sure, but, admittedly, we're partnering with the Chinese so we presumably see it as a bigger opportunity for Fruitflow. We'll know better when the first Chinese products start to come through to our top line. On the other hand ... Our share of the profits over the last six half years are :- 8,30,41,51,88 and 65. So, the half year which ended in March was the first one ( recently anyway ), were our profit share dropped. The trading update meanwhile concentrated on the YoY increase. Hopefully that drop was a one-off, and, come the end of Sept, we get back to growth, but growth really needs new products and we're not seeing many of those at the moment. BB
bareknee
26/7/2017
12:11
AND I suspect blood pressure is common to every race and you are just being annoying.
lafin
26/7/2017
12:06
As far as this share goes there are enough Chinese type people in the world who it will apply to.
lafin
26/7/2017
12:02
Well,that is actually quite interesting-not that I understood it all or even read it all. So does that mean that trials in China may not apply worldwide.? Why have you not mentioned this before? You must have known. What if a person is half Chinese and half European?
lafin
26/7/2017
09:51
Continuing the China theme. Pharmacogenomics ... hxxps://www.fda.gov/downloads/Drugs/ScienceResearch/.../UCM085502.pdf
librag
25/7/2017
22:53
I think R and D is cheaper in China.
lafin
25/7/2017
15:31
I can't bring myself to unfilter you-know-who. I'm confident that activity "toward product formulations" is not going to be relevant research. In fact if we want to waste money and ignore R&D, it's the way to go. :( From memory there was a linkup with PXS R&D and cardiovascular health in general as part of the China deal but TBH I was hoping for something more specific and not half-way round the world. Time will tell.
librag
25/7/2017
14:44
Thank you Lafin. Okay if the research is toward further product formulations as stated then i am happier. At this stage however we really need a large scale product to justify sych research. Imho.
redprince
25/7/2017
12:32
"Thank you,lafin",they said politely. Oh nearly forgot.I agree with BB.
lafin
25/7/2017
12:26
Might be worth looking at relevant RNS again "MOU for a research and development collaboration with By-Health Co., Ltd for Fruitflow® In April 2017 the Company announced that it had entered into a memorandum of understanding with BY-HEALTH Co., Ltd, a substantial listed Chinese dietary supplement business, which is intended to result in a research and collaboration agreement with BY-HEALTH for Fruitflow®. The Company also confirmed separately that Provexis and DSM were working with BY-HEALTH to support the planned launch of some Fruitflow® based products in the Chinese market, with the first launch envisaged in the second half of 2017. The proposed research and collaboration agreement between the Company and BY-HEALTH is intended to focus on BY-HEALTH's research programme into the development of new products that contribute to cardiovascular health, particularly in the field of blood pressure regulation, and it is intended to include a clinical trial which will be conducted in China. It is envisaged that the Company, BY-HEALTH and a third party Chinese research organisation will sign the research and collaboration agreement later this year, with the bulk of the research programme to be completed in 2018. It is envisaged under the MOU that the Company and BY-HEALTH will jointly provide primary funding for the research and collaboration work which will include the assessment of a number of different potential product formulations. Product formulations which are covered under the Company's existing patents would continue to be owned outright by the Company, and the Company would retain proportional joint ownership of any new product formulations developed as part of the project. It is envisaged that the Company will provide scientific and technical support for Fruitflow® to BY-HEALTH throughout the collaboration. In November 2016 the Company announced that its Alliance partner for Fruitflow®, DSM, had entered into a strategic collaboration agreement for Fruitflow® with BY-HEALTH focussing on the development of new products that contribute to cardiovascular health, and the MOU announced by the Company in April is in support of this existing collaboration, whilst ensuring that the Company retains and strengthens its intellectual property holdings. There are more than 230m people in China who are currently thought to have cardiovascular disease, and a significant increase in cardiovascular events is expected in China over the course of the next decade based on population aging and growth alone. China is now the world's second-largest pharmaceuticals market, measured by how much patients and the state spend on drugs. The Company believes that Fruitflow® has the potential to play an important role in the Chinese cardiovascular health market." I presume you are aware that not all of the 230 million people will be able to afford any of this. Also note there are two things happening.One is developing products which will appeal to Chinese market and one is blood pressure research Careful not to confuse the two.
lafin
25/7/2017
12:01
I agree. Any R&D should be focused and clinically relevant. I do worry that the Prof and NoK are more interested in basic science and don't appreciate how useful clinical data might be for the marketing people to play with. I suppose that's where an insightful and forward thinking BoD would help ... not holding my breath on that one.
librag
25/7/2017
11:26
LibraG - my point is that profitability is the key to increasing shareholder wealth. China could be big for us because they are into natural remedies which FF clearly is and the population is enormous. There are grounds for some optimism on those facts alone however that does not to my mind warrant open ended r&d. I would like to see some detail around the proposed r&d and some figures and a timeline too.Otherwise it becomes indefinite jam tomorrow supported by further dilution and inflated salaries.
redprince
25/7/2017
08:26
BB - cant be sure that profitability is 2 years off - you are assuming modest growth.We do not know the potential scale of things in China?
redprince
24/7/2017
14:32
Redprince Purely based on the money coming from DSM from the profit share, we look likely to be loss making for at least a couple more years, so, if we're going to do some more work on the BP( which after all, is why Duttaroy is back on board ) then waiting for cashflow to be positive to fund it isn't really an option. BB
bareknee
24/7/2017
12:12
If they're clever, it won't take much money to show proof of concept and early phase trials. Trouble is, as I found out at the AGM, the academics are not clinically minded and although basic science is necessary, there's a time when small clinical studies will be more useful. Time will tell. Wonder what happened to the total waste of time, memory trial? Likely gone the same way as the chickens. Sigh. Agree re. AGM.
librag
24/7/2017
09:50
LibraG - re research.Tbh if they can keep it under a sensible limit ie it does not become open ended and finance further r&d organically which is some way off, i am okay with that. I genuinely feel that we are going somewhere now. Re agm - the problem was that the material holders did not show up.How some of the people on iii who claim to hold tens of millions can sit back with a laissez faire attitude is beyond me. I will not be going this year - absolutely no point imo given the apathy that 99.9% of holders have consistently demonstrated over the years.
redprince
24/7/2017
08:57
Hi RP, re. China. Potentially I guess, so yes, but frankly I don't know. It seems to me that it's jam tomorrow whichever way one looks at it. Nevertheless, to my untrained eye, the sales numbers are hopeful with significant increases year on year. At least with R&D I have an inkling about what's going on. I'd rather a moderate sum were spent on R&D than marketing but I'm biased. To be fair to him/her, NoR's apathy is consistent. There was zilch response from those who did bother to go to the AGM. Not sure which is worse. Grrrr. Lovely weather!
librag
23/7/2017
14:07
LibraG - i understand like you the potentially enormous market value in being able to demonstrate the bp lowering side of FF. My concern is that we could let this jam tomorrow kind of research essentially dilute us forever and a day until we are forced to sell the ip off. The longer they keep dangling carrots at us the longer they can keep trying to justify ridiculous salary levels and do what they have been doing for 10 years. NOR has little credibility for me now as he claims to be a material holder,is plainly unhappy yet could not make it to an agm to voice his concerns in person.I have told him so quite plainly.Nothing personal. Do you get the impression that China might just give us some legs???
redprince
23/7/2017
09:52
RP; I saw your response to NoR on the other channel. NoR believes that FF is going nowhere in its current form ( I disagree) but if he's right ... there's no point in NOT spending money on R&D, and BP control is an exciting way forward. Those bioactive compounds don't only affect platelets ... Caveat: FF lowers blood pressure but there are a few morons around the boards that ameliorate its good work. Ahem, see above.
librag
23/7/2017
01:02
Swiss Fitness Company selling our Fruitflow for Endurance Athletes:- HTTP://www.sharkfitness.ch/sponser-nitroflow-performance-10-7g-p-2866755.html "Innovative NO Booster for Blood Flow - Oxygen Performance. NITROFLOW PERFORMANCE2 from SPONSER® is a scientifically designed food supplement, with high-polyphenol-containing plant extracts (extracts from 29 plants and L-citrulline). Fruitflow® tomato extract keeps the blood platelets supple, avoids excessive clumping and thus maintains normal blood flow. Suitable for endurance athletes and athletes."
wheelds
21/7/2017
08:23
Ahh buywell.... no you know perfectly well i did not sell any shares in crx to buy a kitchen!! The kitchen came with the house! Wrong again about directors not buying here since 2011. Completely wrong. Just goes to prove how little you actually know here. Why you should wish to comment on a share that you never owned and know so little about is beyond me? As for you not remaining here!! Please. We all know you couldn't stay away even if you tried!
redprince
20/7/2017
17:47
I thought you sold most of your CRX to pay for a kitchen Still since you were not too cheeky Take a look at the financials here hTTps://markets.ft.com/data/equities/tearsheet/financials?s=PXS:LSE I use this link a lot for stock picking Hence I won't be picking this same as the Directors who have not bought since 2011 hTTps://markets.ft.com/data/equities/tearsheet/directors?s=PXS:LSE Learn to drive the above links and more FT info , learn charts and TA and one day you will pick a good one. buybuy I won't be back
buywell3
20/7/2017
13:25
£228k expected this year "148% year on year increase (2016: £92k)." Therefore:- if next year we only get a 100% increase on our £228k we will have 456k ending March 2018, and if it stays around 148% increase we will have £558k and be in profit this time next year. And share price should reflect this factor. And with the China deal and Japan deal year on year increase looks promising.IMHO
wheelds
Chat Pages: 1839  1838  1837  1836  1835  1834  1833  1832  1831  1830  1829  1828  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170728 02:52:08